Which has stronger valuation & earnings, PGNY or CHE?

Chemed has higher revenue and earnings than Progyny. Chemed is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Progyny $1.29B 2.07 $58.52M $1.09 33.19 Chemed $2.53B 2.83 $265.24M $20.90 26.28

Is PGNY or CHE more profitable?

Chemed has a net margin of 10.61% compared to Progyny's net margin of 6.80%. Chemed's return on equity of 35.18% beat Progyny's return on equity. Company Net Margins Return on Equity Return on Assets Progyny 6.80% 19.82% 12.75% Chemed 10.61% 35.18% 19.43%

Does the media refer more to PGNY or CHE?

In the previous week, Progyny had 24 more articles in the media than Chemed. MarketBeat recorded 31 mentions for Progyny and 7 mentions for Chemed. Chemed's average media sentiment score of 0.64 beat Progyny's score of 0.39 indicating that Chemed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 13 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Chemed 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, PGNY or RDNT?

Progyny has higher earnings, but lower revenue than RadNet. RadNet is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Progyny $1.29B 2.07 $58.52M $1.09 33.19 RadNet $2.04B 2.95 -$18.65M -$0.29 N/A

Is PGNY or RDNT more profitable?

Progyny has a net margin of 6.80% compared to RadNet's net margin of -0.94%. Progyny's return on equity of 19.82% beat RadNet's return on equity. Company Net Margins Return on Equity Return on Assets Progyny 6.80% 19.82% 12.75% RadNet -0.94% 3.14% 1.08%

Does the media prefer PGNY or RDNT?

In the previous week, Progyny had 3 more articles in the media than RadNet. MarketBeat recorded 31 mentions for Progyny and 28 mentions for RadNet. RadNet's average media sentiment score of 0.66 beat Progyny's score of 0.39 indicating that RadNet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 13 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral RadNet 8 Very Positive mention(s) 7 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, PGNY or HIMS?

Hims & Hers Health has higher revenue and earnings than Progyny. Hims & Hers Health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Progyny $1.29B 2.07 $58.52M $1.09 33.19 Hims & Hers Health $2.35B 1.96 $128.37M -$0.83 N/A

Does the media favor PGNY or HIMS?

In the previous week, Hims & Hers Health had 34 more articles in the media than Progyny. MarketBeat recorded 65 mentions for Hims & Hers Health and 31 mentions for Progyny. Progyny's average media sentiment score of 0.39 beat Hims & Hers Health's score of -0.25 indicating that Progyny is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 13 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hims & Hers Health 2 Very Positive mention(s) 7 Positive mention(s) 24 Neutral mention(s) 24 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media favor PGNY or LFST?

In the previous week, Progyny had 9 more articles in the media than LifeStance Health Group. MarketBeat recorded 31 mentions for Progyny and 22 mentions for LifeStance Health Group. LifeStance Health Group's average media sentiment score of 0.44 beat Progyny's score of 0.39 indicating that LifeStance Health Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 13 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LifeStance Health Group 6 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, PGNY or BLLN?

Progyny has higher revenue and earnings than Billiontoone. Progyny is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Progyny $1.29B 2.07 $58.52M $1.09 33.19 Billiontoone $436.87M 11.36 $7.45M $0.92 114.29

Is PGNY or BLLN more profitable?

Billiontoone has a net margin of 10.95% compared to Progyny's net margin of 6.80%. Progyny's return on equity of 19.82% beat Billiontoone's return on equity. Company Net Margins Return on Equity Return on Assets Progyny 6.80% 19.82% 12.75% Billiontoone 10.95% 9.16% 6.78%

Does the media prefer PGNY or BLLN?

In the previous week, Progyny had 23 more articles in the media than Billiontoone. MarketBeat recorded 31 mentions for Progyny and 8 mentions for Billiontoone. Progyny's average media sentiment score of 0.39 beat Billiontoone's score of 0.20 indicating that Progyny is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 13 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Billiontoone 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Progyny (PGNY) Competitors

$36.18 -0.40 (-1.09%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$36.15 -0.03 (-0.10%)

As of 11/13/2026 07:30 PM Eastern

Compare

PGNY vs. CHE, RDNT, HIMS, LFST, and BLLN

Should you buy Progyny stock or one of its competitors? Progyny's main competitors and comparable companies include Chemed (CHE), RadNet (RDNT), Hims & Hers Health (HIMS), LifeStance Health Group (LFST), and Billiontoone (BLLN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Progyny compare to Chemed?

Progyny (NASDAQ:PGNY) and Chemed (NYSE:CHE) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Chemed has a net margin of 10.61% compared to Progyny's net margin of 6.80%. Chemed's return on equity of 35.18% beat Progyny's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	6.80%	19.82%	12.75%
Chemed	10.61%	35.18%	19.43%

Progyny presently has a consensus price target of $35.33, suggesting a potential downside of 2.34%. Chemed has a consensus price target of $603.00, suggesting a potential upside of 9.77%. Given Chemed's higher probable upside, analysts plainly believe Chemed is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.73
Chemed	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43

94.9% of Progyny shares are owned by institutional investors. Comparatively, 95.9% of Chemed shares are owned by institutional investors. 9.9% of Progyny shares are owned by company insiders. Comparatively, 3.3% of Chemed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Chemed has higher revenue and earnings than Progyny. Chemed is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	2.07	$58.52M	$1.09	33.19
Chemed	$2.53B	2.83	$265.24M	$20.90	26.28

In the previous week, Progyny had 24 more articles in the media than Chemed. MarketBeat recorded 31 mentions for Progyny and 7 mentions for Chemed. Chemed's average media sentiment score of 0.64 beat Progyny's score of 0.39 indicating that Chemed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	13 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Chemed	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Progyny has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Chemed has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market.

Summary

Chemed beats Progyny on 10 of the 16 factors compared between the two stocks.

How does Progyny compare to RadNet?

Progyny (NASDAQ:PGNY) and RadNet (NASDAQ:RDNT) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

Progyny has a net margin of 6.80% compared to RadNet's net margin of -0.94%. Progyny's return on equity of 19.82% beat RadNet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	6.80%	19.82%	12.75%
RadNet	-0.94%	3.14%	1.08%

Progyny has higher earnings, but lower revenue than RadNet. RadNet is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	2.07	$58.52M	$1.09	33.19
RadNet	$2.04B	2.95	-$18.65M	-$0.29	N/A

94.9% of Progyny shares are owned by institutional investors. Comparatively, 77.9% of RadNet shares are owned by institutional investors. 9.9% of Progyny shares are owned by insiders. Comparatively, 5.1% of RadNet shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Progyny had 3 more articles in the media than RadNet. MarketBeat recorded 31 mentions for Progyny and 28 mentions for RadNet. RadNet's average media sentiment score of 0.66 beat Progyny's score of 0.39 indicating that RadNet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	13 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
RadNet	8 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Progyny currently has a consensus target price of $35.33, suggesting a potential downside of 2.34%. RadNet has a consensus target price of $89.67, suggesting a potential upside of 17.33%. Given RadNet's stronger consensus rating and higher probable upside, analysts clearly believe RadNet is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.73
RadNet	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Progyny has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, RadNet has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market.

Summary

Progyny beats RadNet on 10 of the 17 factors compared between the two stocks.

How does Progyny compare to Hims & Hers Health?

Progyny (NASDAQ:PGNY) and Hims & Hers Health (NYSE:HIMS) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Hims & Hers Health has higher revenue and earnings than Progyny. Hims & Hers Health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	2.07	$58.52M	$1.09	33.19
Hims & Hers Health	$2.35B	1.96	$128.37M	-$0.83	N/A

Progyny has a net margin of 6.80% compared to Hims & Hers Health's net margin of -6.65%. Progyny's return on equity of 19.82% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	6.80%	19.82%	12.75%
Hims & Hers Health	-6.65%	-9.62%	-1.38%

Progyny has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.53, indicating that its share price is 153% more volatile than the broader market.

Progyny presently has a consensus price target of $35.33, indicating a potential downside of 2.34%. Hims & Hers Health has a consensus price target of $31.53, indicating a potential upside of 59.86%. Given Hims & Hers Health's higher probable upside, analysts clearly believe Hims & Hers Health is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.73
Hims & Hers Health	1 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

94.9% of Progyny shares are owned by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are owned by institutional investors. 9.9% of Progyny shares are owned by company insiders. Comparatively, 11.8% of Hims & Hers Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Hims & Hers Health had 34 more articles in the media than Progyny. MarketBeat recorded 65 mentions for Hims & Hers Health and 31 mentions for Progyny. Progyny's average media sentiment score of 0.39 beat Hims & Hers Health's score of -0.25 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	13 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hims & Hers Health	2 Very Positive mention(s)	7 Positive mention(s)	24 Neutral mention(s)	24 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Progyny beats Hims & Hers Health on 10 of the 16 factors compared between the two stocks.

How does Progyny compare to LifeStance Health Group?

Progyny (NASDAQ:PGNY) and LifeStance Health Group (NASDAQ:LFST) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

In the previous week, Progyny had 9 more articles in the media than LifeStance Health Group. MarketBeat recorded 31 mentions for Progyny and 22 mentions for LifeStance Health Group. LifeStance Health Group's average media sentiment score of 0.44 beat Progyny's score of 0.39 indicating that LifeStance Health Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	13 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LifeStance Health Group	6 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Progyny has higher earnings, but lower revenue than LifeStance Health Group. Progyny is trading at a lower price-to-earnings ratio than LifeStance Health Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	2.07	$58.52M	$1.09	33.19
LifeStance Health Group	$1.42B	3.76	$9.66M	$0.19	74.11

94.9% of Progyny shares are owned by institutional investors. Comparatively, 85.5% of LifeStance Health Group shares are owned by institutional investors. 9.9% of Progyny shares are owned by company insiders. Comparatively, 3.5% of LifeStance Health Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Progyny currently has a consensus target price of $35.33, suggesting a potential downside of 2.34%. LifeStance Health Group has a consensus target price of $14.86, suggesting a potential upside of 5.52%. Given LifeStance Health Group's higher possible upside, analysts clearly believe LifeStance Health Group is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.73
LifeStance Health Group	0 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.70

Progyny has a net margin of 6.80% compared to LifeStance Health Group's net margin of 4.29%. Progyny's return on equity of 19.82% beat LifeStance Health Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	6.80%	19.82%	12.75%
LifeStance Health Group	4.29%	4.82%	3.30%

Progyny has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, LifeStance Health Group has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market.

Summary

Progyny beats LifeStance Health Group on 10 of the 17 factors compared between the two stocks.

How does Progyny compare to Billiontoone?

Progyny (NASDAQ:PGNY) and Billiontoone (NASDAQ:BLLN) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, Progyny had 23 more articles in the media than Billiontoone. MarketBeat recorded 31 mentions for Progyny and 8 mentions for Billiontoone. Progyny's average media sentiment score of 0.39 beat Billiontoone's score of 0.20 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	13 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Billiontoone	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Progyny has higher revenue and earnings than Billiontoone. Progyny is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	2.07	$58.52M	$1.09	33.19
Billiontoone	$436.87M	11.36	$7.45M	$0.92	114.29

94.9% of Progyny shares are owned by institutional investors. 9.9% of Progyny shares are owned by company insiders. Comparatively, 50.2% of Billiontoone shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Billiontoone has a net margin of 10.95% compared to Progyny's net margin of 6.80%. Progyny's return on equity of 19.82% beat Billiontoone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	6.80%	19.82%	12.75%
Billiontoone	10.95%	9.16%	6.78%

Progyny currently has a consensus target price of $35.33, indicating a potential downside of 2.34%. Billiontoone has a consensus target price of $124.38, indicating a potential upside of 18.28%. Given Billiontoone's higher possible upside, analysts clearly believe Billiontoone is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.73
Billiontoone	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55

Summary

Progyny beats Billiontoone on 10 of the 15 factors compared between the two stocks.

Get Progyny News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PGNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PGNY vs. The Competition

Export

Metric	Progyny	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.69B	$10.82B	$7.84B	$12.19B
Dividend Yield	N/A	2.54%	2.46%	4.53%
P/E Ratio	33.19	36.37	34.71	28.44
Price / Sales	2.07	2.15	8.66	5.84
Price / Cash	49.69	23.34	21.93	22.49
Price / Book	6.44	3.71	4.35	3.76
Net Income	$58.52M	$335.01M	$3.51B	$390.55M
7 Day Performance	3.85%	-1.06%	-1.49%	-0.33%
1 Month Performance	29.96%	-0.57%	-2.55%	-4.82%
1 Year Performance	47.37%	21.17%	0.92%	-5.83%

Progyny Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PGNY Progyny	2.38 of 5 stars	$36.18 -1.1%	$35.33 -2.3%	+48.2%	$2.69B	$1.29B	33.19	856	Insider Trade
CHE Chemed	3.7943 of 5 stars	$538.84 +2.0%	$603.00 +11.9%	+23.2%	$7.14B	$2.53B	23.95	15,811	Dividend Announcement Insider Trade
RDNT RadNet	3.372 of 5 stars	$78.38 +3.1%	$90.00 +14.8%	+4.0%	$6.32B	$2.04B	182.41	11,264	News Coverage Earnings Report Analyst Forecast Insider Trade High Trading Volume
HIMS Hims & Hers Health	2.8715 of 5 stars	$22.90 -11.9%	$32.43 +41.6%	-45.2%	$6.22B	$2.35B	N/A	2,442	Trending News Earnings Report Analyst Forecast Gap Down High Trading Volume
LFST LifeStance Health Group	3.2144 of 5 stars	$14.60 +6.0%	$13.75 -5.8%	+123.1%	$5.43B	$1.42B	76.85	10,961	News Coverage Analyst Forecast Insider Trade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PGNY) was last updated on 11/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Progyny (PGNY) Competitors

PGNY vs. CHE, RDNT, HIMS, LFST, and BLLN

How does Progyny compare to Chemed?

Summary

How does Progyny compare to RadNet?

Summary

How does Progyny compare to Hims & Hers Health?

Summary

How does Progyny compare to LifeStance Health Group?

Summary

How does Progyny compare to Billiontoone?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGNY vs. The Competition

Progyny Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Progyny (PGNY) Competitors

PGNY vs. CHE, RDNT, HIMS, LFST, and BLLN

How does Progyny compare to Chemed?

Is PGNY or CHE more profitable?

Do analysts prefer PGNY or CHE?

Do institutionals & insiders hold more shares of PGNY or CHE?

Which has stronger valuation & earnings, PGNY or CHE?

Does the media refer more to PGNY or CHE?

Which has more risk and volatility, PGNY or CHE?

Summary

How does Progyny compare to RadNet?

Is PGNY or RDNT more profitable?

Which has higher earnings and valuation, PGNY or RDNT?

Do insiders and institutionals have more ownership in PGNY or RDNT?

Does the media prefer PGNY or RDNT?

Do analysts recommend PGNY or RDNT?

Which has more risk and volatility, PGNY or RDNT?

Summary

How does Progyny compare to Hims & Hers Health?

Which has stronger earnings and valuation, PGNY or HIMS?

Is PGNY or HIMS more profitable?

Which has more volatility and risk, PGNY or HIMS?

Do analysts rate PGNY or HIMS?

Do institutionals and insiders have more ownership in PGNY or HIMS?

Does the media favor PGNY or HIMS?

Summary

How does Progyny compare to LifeStance Health Group?

Does the media favor PGNY or LFST?

Which has higher earnings & valuation, PGNY or LFST?

Do institutionals and insiders hold more shares of PGNY or LFST?

Do analysts prefer PGNY or LFST?

Is PGNY or LFST more profitable?

Which has more risk & volatility, PGNY or LFST?

Summary

How does Progyny compare to Billiontoone?

Does the media prefer PGNY or BLLN?

Which has preferable earnings & valuation, PGNY or BLLN?

Do insiders and institutionals believe in PGNY or BLLN?

Is PGNY or BLLN more profitable?

Do analysts rate PGNY or BLLN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGNY vs. The Competition

Progyny Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools